References

The contents of this research have not been evaluated or approved by the FDA.

  • Andre CM, Hausman J-F, Guerriero G. Cannabis sativa: the plant of the thousand and one molecules. Front Plant Sci.2016;7:19. doi:10.3389/fpls.2016.00019
  • Baron EP. Comprehensive review of medical marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it’s been…. Headache. 2015. 55(6):885-916.doi:10.1111/head.12570.
  • Blessing M, Steenkamp MM, Manzanares J,MarmarCR. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015;12(4):825-836. doi:10.1007/s13311-015-0387-1.
  • Burstein SH,ZurierRB. Cannabinoids, endocannabinoids, and related analogs in inflammation. AAPS J. 2009;11(1):109-119. doi:10.1208/s12248-009-9084-5.
  • Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol.2016;15:270-278. doi:10.1016/S1474-4422(15)00379-8.
  • El-AlfyAT, Ivey K, Robinson K, et al. Antidepressant-like effect of Δ9-tetrahydrocannabinol and other cannabinoids isolated from cannabis sativa L.Pharmacol Biochem Behav. 2010;95(4):432-442.doi:10.1016/j.pbb.2010.03.004.
  • FasinuPS, Phillips S, Elsohly MA, et al. Current status and prospects for cannabidiol preparations as new therapeutic agents. Pharmacotherapy. 2016;36(7):781-796. doi: 10.1002/phar.1780.
  • Fine PG, Rosenfeld MJ. The endocannabinoid system, cannabinoids, and pain. Rambam Maimonides Med J. 2013;4(4):e0022. doi:10.5041/RMMJ.10129.
  • GrotenhermenF, Müller-Vahl K. Medicinal uses of marijuana and cannabinoids. Crit Rev Plant Sci. 2016;35(5-6):378-405. doi:10.1080/07352689.2016.1265360.
  • Hazekamp A,GrotenhermenF. Review on clinical studies with cannabis and cannabinoids 2005-2009. Cannabinoids. 2010;5(special issue):1-21.
  • Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA. 2015;313(24):2474–2483. doi:10.1001/jama.2015.6199.
  • Kaur R,AmbwaniSR, Singh S. Endocannabinoid system: A multi-facet therapeutic target. Curr Clin Pharmacol. 2016;11(2):110-7. doi:10.2174/1574884711666160418105339.
  • Pearce DD,MitsourasK, Irizarry KJ. Discriminating the effects of cannabis sativa and cannabis indicia: a web survey of medical cannabis users. J Altern Complement Med. 2014;20(10):787-791.doi:10.1089/acm.2013.0190.
  • PisantiS, Malfitano AM, Ciaglia E, et al. Cannabidiol: state of the art and new challenges for therapeutic applications. Pharmacol Ther. 2017;175:133-150. doi:10.1016/j.pharmthera.2017.02.041.
  • Rong C, Lee Y, Carmona NE, et al. Cannabidiol in medical marijuana: research vistas and potential opportunities.PharmacolRes. 2017;121:213-218. doi:10.1016/j.phrs.2017.05.005.
  • Russo E, Guy GW. The therapeutic rationale for combining tetrahydrocannabinol andcanabidiol. Med Hypotheses. 2006;66(2):234-246.doi:10.1016/j.mehy.2005.08.026.
  • Russo EB. Cannabinoids in the management of difficult to treat pain.TherClin Risk Manag. 2008;4(1):245-259. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503660 Accessed September 18, 2018.
  • TzadokM, Uliel-Siboni S, Liinder I, et al. CBD-enriched medical cannabis for intractable pediatric epilepsy: the current Israeli experience. Seizure. 2016;35:41-44. doi:10.1016/j.seizure.2016.01.004.
  • Walsh Z, Callaway R, Belle-Isle L, et al. Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use. Int J Drug Policy. 2013;24(6):511-516.doi:10.1016/j.drugpo.2013.08.010.